The global viral vector and plasmid DNA manufacturing market size was valued at USD 591 million in 2020 and is projected to expand at a robust CAGR during the forecast period, 2021–2028. The growth of the market is attributed to increasing demand for viral vector-based vaccinations for contagious diseases
Viral vectors are widely utilized by molecular techniques to transport genetic elements into cells. Viruses evolve specific molecular pathways for efficient transport of their DNA inside cells infected by them only through the transduction process.
Viral vectors and plasmid DNA are used in gene therapy to treat a variety of diseases such as heart abnormalities, metabolic problems, cancers, and neurological disorders. Viral vectors based on adenoviruses and herpes simplex viruses are finding more usage in vaccine production and innovative medication discovery.
Market Trends, Drivers, Restraints and Opportunities
- Increasing prevalence of cancer is anticipated to drive the market growth.
- Rising number of gene therapy applicants, which are progressing rapidly through stage of clinical development, is estimated to drive viral vector and plasmid DNA industrial production.
- Growing funding for gene therapy research and development activities as well as increasing public awareness about gene therapy are fueling the market growth.
- The risk of mutation as well as the high cost of genetic testing and other impediments to gene therapy can hamper the market growth.
- The global market for synthetic genes and the unexplored developing market potential are estimated to generate opportunity for market participants during the projection period.
- The COVID-19 pandemic has provided significant opportunities for market participants and has increased demand for viral vectors, resulting in increased revenues for viral vector manufacturers.
Scope of the Report
The report on the global viral vector and plasmid DNA manufacturing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Applications (Genetic Disorders, Infectious Diseases, Cancers, and Others), and Product Types (Viral Vector, Non-viral Vector, and Plasmid DNA)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Thermo Fisher Scientific; SIRION Biotech; Fujifilm Diosynth Biotechnologies; Merck KGaA Inc.; Cognate BioServices Inc. (Cobra Biologics); and Others
Viral Vector and Plasmid DNA Manufacturing Market Segment Insights
Genetic disorder segment is expected to grow at a rapid pace
Based on applications, the market is divided into genetic disorders, infectious diseases, cancers, and others. The genetic disorders segment is expected to grow at a rapid pace during the forecast period. Growing engagement of the scientific community in gene and cell therapy research activities is projected to propel the global demand for viral vectors. However, the cancer segment is anticipated to dominate the industry. This segment contributed for more than for 35% revenue in 2020. Viruses have shown to be an effective vector for the generation of gene therapy against a variety of different cancers.
Viral vector segment is projected to expand at a considerable CAGR
On the basis of product types, the viral vector and plasmid DNA manufacturing market is segregated viral vector, non-viral vector, and plasmid DNA. The viral vector segment is anticipated to account for a major market share during the forecast period. Increasing use of viral vectors in vaccine production owing to their operational efficiencies and advantages such as ability to generate a wide immunological response, safety profiles, and ease of manufacture.
Middle East & Africa anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the Middle East & Africa is expected to constitute a key share of the market during the projected period. Novel viral vectors are rapidly evolving, and numerous researchers are working on replacing harmful genes with therapeutic genes. However, North America is anticipated to expand at a rapid pace during the forecast period The North American viral vector and plasmid DNA production industry is currently experiencing significant expansion owing to rapid innovation in the development of viral vector product methods.
Segments Covered in the Report
The global viral vector and plasmid DNA manufacturing market has been segmented on the basis of
- Genetic Disorders
- Infectious Diseases
- Viral Vector
- Non-viral Vector
- Plasmid DNA
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Thermo Fisher Scientific
- SIRION Biotech
- Fujifilm Diosynth Biotechnologies
- Merck KGaA Inc.
- Cognate BioServices Inc. (Cobra Biologics)
The market is very competitive in nature owing to the presence of many major players. Some of the major players competing in the global viral vector and plasmid DNA manufacturing market are Thermo Fisher Scientific; SIRION Biotech; Fujifilm Diosynth Biotechnologies; Merck KGaA Inc.; Cognate BioServices Inc. (Cobra Biologics), and Others